Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus.
Theocharis KoufakisSpirydon N KarrasPantelis ZebekakisRamzi AjjanKalliopi KotsaPublished in: Expert opinion on biological therapy (2018)
T2DM: Type 2 Diabetes Mellitus; HbA1C: Hemoglobin A1c; OHA: Oral Hypoglycemic Agents; STIT: Short-term Insulin Treatment; CSII: Continuous Subcutaneous Insulin Infusion; MDI: Multiple Daily Injections; PPG: Postprandial Plasma Glucose; FPG: Fasting Plasma Glucose; HOMA-b: Homeostasis Model Assessment of beta-cell function; TDD: Total Daily Insulin Dose; DI: Disposition Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; ROS: Reactive Oxygen Species; TNF: Tumor Necrosis Factor; GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent Insulinotropic Polypeptide; BMI: Body Mass Index; CV: Cardiovascular; DR: Diabetic Retinopathy; SU: Sulfonylurea; IGI: Insulinogenic Index.
Keyphrases
- glycemic control
- blood glucose
- type diabetes
- insulin resistance
- body mass index
- diabetic retinopathy
- reactive oxygen species
- rheumatoid arthritis
- physical activity
- metabolic syndrome
- adipose tissue
- optical coherence tomography
- cardiovascular disease
- weight gain
- cell death
- blood pressure
- oxidative stress
- pseudomonas aeruginosa
- combination therapy
- polycystic ovary syndrome
- biofilm formation